Suppr超能文献

1975 - 2004年英格兰和威尔士前列腺癌死亡率、发病率及治疗的长期趋势

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.

作者信息

Hussain Sabina, Gunnell David, Donovan Jenny, McPhail Sean, Hamdy Freddie, Neal David, Albertsen Peter, Verne Julia, Stephens Peter, Trotter Caroline, Martin Richard M

机构信息

Department of Social Medicine, University of Bristol, Bristol, UK.

出版信息

BJU Int. 2008 Mar;101(5):547-55. doi: 10.1111/j.1464-410X.2007.07338.x. Epub 2008 Jan 10.

Abstract

OBJECTIVE

To aid the interpretation of the trends in prostate cancer mortality, which declined in the UK in the early 1990 s for unknown reasons, by investigating prostate cancer death rates, incidence and treatments in England and Wales in 1975-2004.

METHODS

Join-point regression was used to assess secular trends in mortality and incidence (source: Office of National Statistics), radical prostatectomy and orchidectomy (source: Hospital Episode Statistics database) and androgen-suppression drugs (source: Intercontinental Medical Statistics).

RESULTS

Prostate cancer mortality declined from 1992 (95% confidence interval, CI, 1990-94). The relative decline in mortality to 2004 was greater and more sustained amongst men aged 55-74 years (annual percentage mortality reduction 2.75%; 95% CI 2.33-3.18%) than amongst those aged >or=75 years (0.71%, 0.26-1.15%). The use of radical prostatectomy increased between 1991 (89 operations) and 2004 (2788) amongst men aged 55-74 years. The prescribing of androgen suppression increased between 1987 (33,000 prescriptions) and 2004 (470,000).

CONCLUSIONS

The decrease in prostate cancer mortality was greater amongst men aged 55-74 years than in those aged >or=75 years, but pre-dated the substantial use of prostate-specific antigen screening and radical prostatectomy in the UK. An increase in radical therapy amongst younger groups with localized cancers and screen-detected low-volume locally advanced disease as a result of stage migration, as well as prolonged survival from increased medical androgen suppression therapy, might partly explain recent trends.

摘要

目的

通过调查1975 - 2004年英格兰和威尔士前列腺癌的死亡率、发病率及治疗情况,辅助解释前列腺癌死亡率在20世纪90年代初于英国不明原因下降的趋势。

方法

采用连接点回归评估死亡率和发病率的长期趋势(数据来源:国家统计局)、根治性前列腺切除术和睾丸切除术(数据来源:医院事件统计数据库)以及雄激素抑制药物(数据来源:洲际医学统计)。

结果

前列腺癌死亡率自1992年开始下降(95%置信区间,CI,1990 - 94)。与75岁及以上男性相比,55 - 74岁男性至2004年死亡率的相对下降幅度更大且更持续(年死亡率降低2.75%;95% CI 2.33 - 3.18%)(年死亡率降低0.71%,0.26 - 1.15%)。1991年(89例手术)至2004年(2788例),55 - 74岁男性根治性前列腺切除术的使用量增加。1987年(33000张处方)至2004年(470000张),雄激素抑制药物的处方量增加。

结论

55 - 74岁男性前列腺癌死亡率的下降幅度大于75岁及以上男性,但早于英国广泛使用前列腺特异性抗原筛查和根治性前列腺切除术。由于分期迁移,年轻组局部癌症和筛查发现的低体积局部晚期疾病的根治性治疗增加,以及雄激素抑制治疗增加导致生存期延长,可能部分解释了近期的趋势。

相似文献

1
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.
BJU Int. 2008 Mar;101(5):547-55. doi: 10.1111/j.1464-410X.2007.07338.x. Epub 2008 Jan 10.
5
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Cochrane Database Syst Rev. 2002(1):CD003506. doi: 10.1002/14651858.CD003506.
8
Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.
9
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Ann Intern Med. 2008 Mar 18;148(6):435-48. doi: 10.7326/0003-4819-148-6-200803180-00209. Epub 2008 Feb 4.

引用本文的文献

1
The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies.
Epidemiology. 2020 May;31(3):432-440. doi: 10.1097/EDE.0000000000001132.
3
Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
PLoS One. 2017 Feb 3;12(2):e0171495. doi: 10.1371/journal.pone.0171495. eCollection 2017.
5
Developing a robotic prostatectomy service and a robotic fellowship programme - defining the learning curve.
Curr Urol. 2013 Feb;7(3):136-44. doi: 10.1159/000356266. Epub 2014 Feb 10.
7
8
Mast cells as a potential prognostic marker in prostate cancer.
Dis Markers. 2013;35(6):711-20. doi: 10.1155/2013/478303. Epub 2013 Nov 11.
9
MRI for men undergoing active surveillance or with rising PSA and negative biopsies.
Nat Rev Urol. 2010 Oct;7(10):543-51. doi: 10.1038/nrurol.2010.143.

本文引用的文献

3
Commentary: Screening for prostate cancer.
Int J Epidemiol. 2007 Feb;36(1):30. doi: 10.1093/ije/dyl305. Epub 2007 Jan 27.
4
Insulin-like growth factor-I and growth in height, leg length, and trunk length between ages 5 and 10 years.
J Clin Endocrinol Metab. 2006 Jul;91(7):2514-9. doi: 10.1210/jc.2006-0388. Epub 2006 May 2.
6
Prostate cancer: screening approaches.
Br J Hosp Med (Lond). 2005 Nov;66(11):623-6. doi: 10.12968/hmed.2005.66.11.20023.
7
Does current evidence justify prostate cancer screening in Europe?
Nat Clin Pract Oncol. 2005 Nov;2(11):538-9. doi: 10.1038/ncponc0349.
8
Radical prostatectomy versus watchful waiting in early prostate cancer.
N Engl J Med. 2005 May 12;352(19):1977-84. doi: 10.1056/NEJMoa043739.
9
20-year outcomes following conservative management of clinically localized prostate cancer.
JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验